Researchers hunting for antifungal compounds in a soil sample from Easter Island in 1972 found something else. The molecule was named rapamycin after the island’s Polynesian name, Rapa Nui. It is also sold as sirolimus.
The FDA approved it in 1999 as an immunosuppressant, to stop transplant patients’ bodies from rejecting a new organ. That is the setting most doctors know it from, at high daily doses. Over the past several years it has become one of the most discussed drugs in longevity research.
What it does in cells
Rapamycin blocks a protein called mTOR, the mechanistic target of rapamycin. Think of mTOR as the body’s grow-and-go signal. When it is active, cells build protein, add mass and divide. When it is turned down, cells shift to upkeep: they clear damaged components and recycle debris, a process called autophagy. Autophagy declines with age. One idea behind the drug is that many age-related diseases come from cells that keep growing, inflaming and secreting long after they should have stopped.
Mice, dogs and people
The animal evidence is the strongest. In the National Institute on Aging’s Interventions Testing Program, rapamycin lengthened the lives of mice by 9 to 14 percent. It did so even when treatment began late in life, at an age comparable to 60 in a human. Most lifespan-extending drugs in animals only work if they are started young. Mouse studies have also pointed to better heart function, immune performance and cognitive measures. In dogs, the Dog Aging Project is running rapamycin trials aimed at cardiac aging, with preliminary results suggesting better heart function at low doses.
Human data is thinner. No large randomized trials of rapamycin for longevity in healthy people exist, because a study that runs for a decade is hard and costly. A 2014 study in Science Translational Medicine found that everolimus, a rapamycin analog, improved the response to flu vaccination in adults over 65 by up to 20 percent. Smaller studies have hinted at improvements in biological-age markers, though that work is preliminary. Several small studies and physician case series report that intermittent low doses, typically 1 to 6 milligrams weekly, are generally well tolerated in healthy adults.
What nobody knows yet
The best dose and schedule for people are unknown. The once-a-week protocol of 5 to 6 milligrams that many physicians use comes from pharmacokinetics and animal data, not from a human trial comparing regimens. Nobody has studied decades of use in healthy people. And mTOR inhibition is not always welcome: some evidence suggests it may blunt muscle building, so some protocols steer users away from the drug for 24 to 48 hours around hard training.
Reported side effects at low doses include mouth sores, the most common, along with raised triglycerides and sometimes LDL cholesterol, which is why lipid monitoring is standard. Delayed wound healing is a worry at high doses and less documented at low ones. Doctors say anyone on the drug should tell clinicians before vaccines or procedures.
Using it for aging is off-label, and no rapamycin-based drug is approved for that purpose. Physicians who prescribe it for longevity typically order baseline blood tests for lipids, glucose, blood counts and kidney function, then follow up with monitoring. People with active infections, planned surgery or pregnancy are generally poor candidates.
Consult your doctor for medical advice.
